Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403416 · ClinicalTrials.gov registry record · Phase 1
Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 215
- Enrollment target
NCT00403416: Completed Phase 1 study, sponsored by Novartis Pharmaceuticals.
NCT00403416 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 215 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (258% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00403416, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 215 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of AEB071 in preventing acute rejections after kidney transplantation, when combined with tacrolimus for the first 3 months and with myfortic thereafter.
Interventions
- DRUG AEB071
- DRUG Mycophenolic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
What the finished NCT00403416 record still lists
NCT00403416 is an interventional study that assigns participants to a tested intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (258% higher).
The record links to 0 conditions, and to 2 interventions - of which AEB071 is the first listed.
NCT00403416 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00403416 about?
NCT00403416 is a clinical study titled "Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients". This study will evaluate the efficacy and safety of AEB071 in preventing acute rejections after kidney transplantation, when combined with tacrolimus for the first 3 months and with myfortic thereafter.
What is the current status of trial NCT00403416?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 215 participants. The study started on 2006-10. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00403416?
The interventions under investigation include: AEB071 (DRUG), Mycophenolic Acid (DRUG).
Who is sponsoring clinical trial NCT00403416?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00403416's enrollment target sits among peer trials
215 243rd of 2000 higher than 1,757 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05134012 · 215 participants · Phase 3
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
- NCT05169970 · 215 participants · Phase 2
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
- NCT05197270 · 215 participants · Phase 1
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- NCT05230199 · 215 participants · NA
Sensory Optimization of the Hospital Environment
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia